国际动态存档（2015年8月4期）

8/25 100 Most Influential People in Healthcare - 2015
8/25 NCCN Will Rate Cancer Drugs for Costs, Benefits and Side Effects : Powerful cancer alliance joins cost-effectiveness drug crusade
8/25 Immunotherapy ‘revolutionary’ for lung cancer, but questions remain about cost, biomarkers
8/25 Optimizing effectiveness of CAR T cell therapy in lymphoma highlighted in special nordic issue
8/25 FDA and EMA accept regulatory applications for Boehringer Ingelheim's Gilotrif® (afatinib) for treatment of advanced squamous cell carcinoma of the lung
8/25 Austin Cancer Drugs Developer Mirna Therapeutics Files for an IPO
8/24 What Time is It? Time to Get a Wearable Strategy
8/24 FDA extends use of Promacta in young children with rare blood disorder
8/24 Takeda takes unexpected blow as blockbuster Velcade patent ruled invalid
8/24 Samsung, Biogen lining up a $1B IPO for biosimilar joint venture: WSJ
8/24 What Causes Variations in Review at CDER? It's All About the Designation
8/24 BRIEF-Astrazeneca and Peregrine Pharma to collaborate on immuno-oncology combination clinical trial of bavituximab and durvalumab in solid tumors
8/24 PARP Inhibitors Move Into the Limelight
8/24 UPDATED: BioMarin sells its PhIII cancer drug to Medivation for $570M
8/24 Esperance and M.D. Anderson Cancer Center collaborate to accelerate development of EP-100 in ovarian and breast cancers
8/21 Majority in U.S. favor government steps to cut drug prices
8/21 Lilly, Sanofi, Novo among many pharma players to throw off big price gains in H1
8/21 ViewPoints: Novartis eyes multiple sclerosis expansion but Roche's ocrelizumab could change the game
8/21 The Female Libido Pill and Five Other Drugs That Can Be Defeated by Their Own Side Effects
8/21 The FDA Is Basically Approving Everything. Here's The Data To Prove It
8/21 Cellectar Biosciences Introduces Phospholipid Ether-Drug Conjugate (PDC) Platform for Targeted Delivery of Chemotherapeutics
8/21 Takeda Announces European Medicines Agency Acceptance of Ixazomib’s Marketing Authorization Application for Patients with Relapsed/Refractory Multiple Myeloma
8/21 EMA validates Pfizer’s MAA for Ibrance in combination with endocrine therapy for HR-positive/HER2-metastatic breast cancer
8/21 Will Kyle Bass’s Drug Patent Gambit Pay Off? He’ll Soon Find Out
8/21 Takeda’s Velcade Patent Overturned in Win for Generics
8/20 In a first for diabetes, Lilly and Boehringer's Jardiance prevents heart attacks, strokes in trial
8/20 Aurobindo Pharma receives USFDA Approval for Omeprazole Delayed-release Capsules
8/20 First trial targeting mutation, not cancer type, gives mixed results
8/20 UPDATED: FDA to Sprout: Forget advertising your sex-drive med till 2017
8/20 Is ketamine the best hope for curing major depression?
8/20 Sonidegib Approved in Europe for Basal Cell Carcinoma
8/20 Lynparza Improves Overall Survival in High-Risk Gastric Cancer
8/20 Fitch: Even as FDA Approvals Slow, Cancer Treatments Progress in Pharma R&D Pipeline
8/20 Pharma companies rank high on Forbes’ most innovative list
8/20 Valeant Pharmaceuticals To Acquire Sprout Pharmaceuticals
8/19 AbbVie hands United a record $350M payoff for a speedy FDA review voucher
8/19 Harvard/MIT group sees promise of a targeted IBD drug delivery tech
8/19 Is the biomedical research system broken? Johns Hopkins says yes
8/19 Merck's Januvia powerhouse could feel the heat from device challenger
8/19 Little-known Lannett tops Fortune's fastest-growing list, thanks to big price hikes